Pfizer COVID pill to be rolled out for vulnerable people in the UK


The United Kingdom will start rolling out Pfizer’s COVID-19 pill to vulnerable people next month, the health ministry says, targeting the treatment at people with compromised immune systems for whom the vaccine can be less effective.

The health ministry said that Pfizer’s antiviral treatment Paxlovid, a combination of Pfizer’s pill with an older antiviral ritonavir, will be made available to thousands of people from February 10.

In the video above, TGA approves Pfizer boosters for teens.

“It is fantastic news that this new treatment, the latest cutting-edge drug that the NHS is rolling out through new COVID-19 medicine delivery units, will now be available to help those at highest risk of COVID-19,” National Health Service medical director Stephen Powis said.

FILE – This image provided by Pfizer shows the company’s COVID-19 Paxlovid pills. Credit: thomas hansmann.fotograf/AP

“Trials have shown it can reduce hospitalisation and risk of death by 88 per cent, meaning we’ll be in the best position to save thousands of lives.”

The UK has ordered 2.75 million courses of Paxlovid and the government said that it would set out further details on access to the treatment soon but that people who are immunocompromised, cancer patients or those with Down’s Syndrome could be able to access it directly.

It is the second antiviral being rolled out in the UK after molnupiravir, a pill made by Merck and Ridgeback Biotherapeutics which is being deployed to patients through the Panoramic trial.


Read original article here

Denial of responsibility! Yours Headline is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.

Leave A Reply

Your email address will not be published.